Is the top of the schedule the goal?

Answer

No. It is the top of the schedule. Labels describe increasing only if more effect is needed and the current amount is tolerated.

In more detail

The trial figures that get quoted in headlines were mostly measured in the highest arms, which is why the top number carries so much weight in conversation. But the same trials show meaningful separation at the middle amounts too: SURMOUNT-1 reported mean reductions of roughly 16%, 21% and 22.5% at 5 mg, 10 mg and 15 mg tirzepatide by week 72, so the gap between the middle and the top is far smaller than the gap between the bottom and the middle. Labeling in this class consistently frames higher steps as conditional rather than as a destination.

Source

SURMOUNT-1 (Jastreboff 2022, PMID 35658024) and approved labeling.

Educational use only, never medical advice. No doses.